Novartis Concealed Manipulated Data From FDA While Seeking Approval For $2.1M Gene Therapy Drug

Officials say the issue doesn't put patients at risk, but the drugmaker could face penalties for withholding the information. The news has also unsettled an industry where many are racing to be the first to come out with these expensive gene therapies.

from Kaiser Health News https://ift.tt/33kDho3